84,162 results match your criteria Lung Cancer Oat Cell Small Cell

Serum Levels of Sirtuin-1 in Patients with Lung Cancer and its Association with Karnofsky Performance Status.

Acta Biomed 2021 May 12;92(2):e2021012. Epub 2021 May 12.

a:1:{s:5:"en_US";s:125:"Internal Medicine Department (Pulmonary Division), Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran";}.

Background: Lung cancer is a major cause of cancer-related deaths worldwide. There are conflicting results regarding the role of sirtuin-1 in cancer. This study aimed to evaluate the serum sirtuin-1 levels in patients with lung cancer and its relationship with the quality of life based on Karnofsky performance statue scale (KPS). Read More

View Article and Full-Text PDF

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report.

Ann Transl Med 2021 Apr;9(8):724

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Immunotherapy has revolutionized lung cancer management and revitalized the field of tumor immunology. Anti-programmed death 1 (anti-PD-1) immunotherapy can significantly improve the survival of patients with advanced non-small cell lung cancer (NSCLC), but its role in neoadjuvant therapy of local advanced NSCLC remains uncertain. Herein, we reported a case from a clinical trial of our department, a patient who achieved excellent outcome after neoadjuvant immunotherapy and chemotherapy for local advanced NSCLC. Read More

View Article and Full-Text PDF

CD2 T-helper 17-like cells differentiated from a CD133 subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma.

Ann Transl Med 2021 Apr;9(8):687

Institute of Basic Medicine, Hebei Medical University, Shijiazhuang, China.

Background: Cancer stem cells (CSCs) give rise to a diverse variety of differentiated cells, which comprise the bulk of the tumor microenvironment (TME). However, the exact multi-directional differentiation potential of CSCs has not been fully clarified. This study was designed to explore whether CSCs differentiate into cellular components of the TME to promote the growth of lung carcinoma. Read More

View Article and Full-Text PDF

The G4 Resolvase DHX36 Possesses a Prognosis Significance and Exerts Tumour Suppressing Function Through Multiple Causal Regulations in Non-Small Cell Lung Cancer.

Front Oncol 2021 27;11:655757. Epub 2021 Apr 27.

Cardiff China Medical Research Collaborative, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Lung cancer is one of the most prevalent cancers in both men and women worldwide. The nucleic acid G4 structures have been implicated in the transcriptional programmes of cancer-related genes in some cancers such as lung cancer. However, the role of the dominant G4 resolvase DHX36 in the progression of lung cancer remains unknown. Read More

View Article and Full-Text PDF

Updates in the molecular pathology of non-small cell lung cancer.

Semin Diagn Pathol 2021 Apr 25. Epub 2021 Apr 25.

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia. Electronic address:

An understanding of the molecular pathology of non-small cell lung cancer (NSCLC) is important for pathologists as molecular characterization is now required for treatment decisions in advanced stage disease. While assessment for EGFR mutations, ALK and ROS1 fusions, and in some countries BRAF mutations, is now standard practice, other oncogenic mutations are also emerging that may impact routine clinical practice including alterations involving KRAS, NTRK, RET, MET and HER2. In addition, molecular pathology alterations of NSCLC are associated with responses to immune checkpoint therapy and are being increasingly investigated. Read More

View Article and Full-Text PDF

Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.

J Enzyme Inhib Med Chem 2021 Dec;36(1):987-999

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.

As one of the most lethal malignancies, lung cancer is considered to account for approximately one-fifth of all malignant tumours-related deaths worldwide. This study reports the synthesis and biological assessment of two sets of 3-methylbenzofurans (, , and ) and 3-(morpholinomethyl)benzofurans (, , and ) as potential anticancer agents towards non-small cell lung carcinoma A549 and NCI-H23 cell lines, with VEGFR-2 inhibitory activity. The target benzofuran-based derivatives efficiently inhibited the growth of both A549 and NCI-H23 cell lines with IC spanning in ranges 1. Read More

View Article and Full-Text PDF
December 2021

Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database.

Front Oncol 2021 26;11:647546. Epub 2021 Apr 26.

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Non-small cell lung carcinoma (NSCLC) with ipsilateral and/or subcarinal mediastinal lymphatic spread (N2) is a heterogeneous disease. The role of surgical resection in patients with N2 NSCLC remains controversial and no survival-based definition of "resectable N2" exists. The purpose of this study is to evaluate the factors that potentially affect the survival of N2 NSCLC patients who receive surgical resection and to define "resectable N2" based on the survival benefits. Read More

View Article and Full-Text PDF

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.

Front Oncol 2021 26;11:626566. Epub 2021 Apr 26.

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.

Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment. Recently, favorable immune checkpoint blockade responses have been observed in PPLELC. This study aimed to review the effects of this regimen in patients with advanced PPLELC. Read More

View Article and Full-Text PDF

Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung.

Cell Death Dis 2021 May 12;12(5):472. Epub 2021 May 12.

Department of Pathology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, 350001, China.

Small-cell carcinoma of the esophagus (SCCE) is a rare and aggressive cancer. Although several consistent genomic changes were observed previously between SCCE and small-cell lung cancer (SCLC), detailed mutational landscapes revealing discrepancies in genetic underpinnings of tumorigenesis between these two cancers are scarce, and little attention has been paid to answer whether these genetic alterations were related to the prognosis. Herein by performing whole-exome sequencing of 48 SCCE and 64 SCLC tumor samples, respectively we have shown that the number of driver mutations in SCCE was significantly lower than in SCLC (p = 0. Read More

View Article and Full-Text PDF

Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide.

Sci Transl Med 2021 May;13(593)

Division of Molecular Radiation Biology, Department of Radiation Oncology, and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Avasopasem manganese (AVA or GC4419), a selective superoxide dismutase mimetic, is in a phase 3 clinical trial (NCT03689712) as a mitigator of radiation-induced mucositis in head and neck cancer based on its superoxide scavenging activity. We tested whether AVA synergized with radiation via the generation of hydrogen peroxide, the product of superoxide dismutation, to target tumor cells in preclinical xenograft models of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and pancreatic ductal adenocarcinoma. Treatment synergy with AVA and high dose per fraction radiation occurred when mice were given AVA once before tumor irradiation and further increased when AVA was given before and for 4 days after radiation, supporting a role for oxidative metabolism. Read More

View Article and Full-Text PDF

PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.

Thorac Cancer 2021 May 12. Epub 2021 May 12.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Backgroud: Recent studies have indicated that programmed cell death-ligand 1 (PD-L1) and cluster of differentiation 47 (CD47) play an essential role in tumor immune evasion and may serve as potential targets for combined immunotherapy. The aim of our study was to evaluate the PD-L1/CD47 expression status in lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD), and explore its survival impact and relevance with the immune microenvironment.

Methods: The specimens from 190 LUSC and 240 LUAD patients who underwent intent-to-treat surgeries were retrospectively collected for immunohistochemistry assays of PD-L1, CD47, cluster of differentiation 8 (CD8), and cluster of differentiation 68 (CD68). Read More

View Article and Full-Text PDF

Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.

Med Sci Monit 2021 May 12;27:e929333. Epub 2021 May 12.

Department of Respiratory Medicine, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China (mainland).

BACKGROUND Lung adenocarcinoma (LUAD) is a type of non-small cell carcinoma. Its pathogenesis is being explored and there is no cure for the disease. MATERIAL AND METHODS The Gene Expression Omnibus (GEO) was searched to obtain data on expression of messenger RNA. Read More

View Article and Full-Text PDF

SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors.

Am J Clin Pathol 2021 May 12. Epub 2021 May 12.

Department of Laboratory Medicine and Pathology, Rochester, MN, USA.

Objectives: To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors.

Methods: Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Read More

View Article and Full-Text PDF

A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.

Ann Palliat Med 2021 May 8. Epub 2021 May 8.

Department of Neuro-Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China.

Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. However, the efficacy and optimal dosage of osimertinib in the treatment of NSCLC patients with LM who harbor uncommon EGFR mutations have yet to be fully investigated. Read More

View Article and Full-Text PDF

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.

Ann Palliat Med 2021 Apr 21. Epub 2021 Apr 21.

Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.

Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have a favorable and durable treatment response, almost all patients will eventually acquire resistance and develop disease progression. Re-administration of first and second-generation EGFR TKIs has been successfully executed in advanced non-small cell lung cancer (NSCLC) subsequent to EGFR-TKI resistance. However, osimertinib rechallenge following osimertinib resistance in EGFR T790M-negative patient is less explored. Read More

View Article and Full-Text PDF

Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy.

Respirol Case Rep 2021 Jun 7;9(6):e00757. Epub 2021 May 7.

Department of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan.

There is limited evidence for the treatment of sarcomatoid lung carcinoma, especially spindle cell carcinoma (SpCC) because of the rarity of disease. Although the efficacy of combination of chemotherapy and immunotherapy (i.e. Read More

View Article and Full-Text PDF

[Strategy with Immune Checkpoint Inhibitors for ES‒SCLC].

Gan To Kagaku Ryoho 2021 Apr;48(4):493-498

Division of Medical Oncology, Dept. of Internal Medicine, Teikyo University School of Medicine.

As a treatment strategy for various carcinoma, immune checkpoint inhibitors(ICIs)can prolong overall survival with ICI monotherapy, ICIs combination therapy, or chemotherapy and ICI combination therapy. It has been validated in clinical trials and is recognized as a key drug in the treatment of cancer. In two large phase Ⅲ trials(IMpower133 and CASPIAN), the strategy of anti PD‒L1 antibody, such as atezolizumab and durvalumab, with chemotherapy was prolonged overall survival compared with the chemotherapy alone in extensive stage small cell lung cancer. Read More

View Article and Full-Text PDF

[How to Preserve QOL of Patients with Small Cell Lung Cancer-Cutting‒Edge Treatment of Brain and Bone Metastases].

Gan To Kagaku Ryoho 2021 Apr;48(4):486-492

Dept. of Thoracic Oncology, Kobe Minimally Invasive Cancer Center.

Small cell lung cancer(SCLC)frequently develops both brain metastases and bone metastases. Considering the negative effects on quality of life(QOL), it is essential to manage properly these metastases. In patients with limited‒disease(LD) SCLC who have a good response to chemoradiotherapy, prophylactic cranial irradiation(PCI)is given to decrease brain metastases. Read More

View Article and Full-Text PDF

[Comprehensive Genomic Analysis for Small Cell Lung Cancer].

Gan To Kagaku Ryoho 2021 Apr;48(4):476-485

Dept. of Thoracic Oncology, National Cancer Center Hospital East.

Small cell lung cancer(SCLC)is one of the histological types of lung cancer showing the worst prognosis, and is often diagnosed as an inoperable advanced stage disease. Recently, several comprehensive genomic analyses for SCLC have shown that inactivating mutations of tumor suppressor genes such as TP53 and RB1 and MYC family gene amplifications are involved in the development and progression of SCLC. However, actionable gene alterations for targeted therapies have not yet been identified, and there has been no significant advance in the development of targeted therapies for SCLC. Read More

View Article and Full-Text PDF

[Pathological and Molecular Biological Classification of Small Cell Lung Cancer].

Yasushi Yatabe

Gan To Kagaku Ryoho 2021 Apr;48(4):472-475

Dept. of Diagnostic Pathology, National Cancer Center Hospital.

The name of small cell carcinoma is becoming unified with neuroendocrine carcinoma in many other cancers except lung cancer, and following this trend, small cell carcinoma of the lung categorized into a subtype under neuroendocrine carcinoma in the 2015 WHO classification. However, small cell carcinoma has been retained and remain as a distinct entity. In this article, I introduced the history and current concept of small cell lung cancer classification, as well as the molecular biological classification of small cell lung cancer based on 4 definitive molecules, ASCL1, NEUROD1, YAP1, and POU2F3, proposed in 2019. Read More

View Article and Full-Text PDF

[The Significance of Surgical Biopsy in Case of the Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Postoperative Recurrence of Lung Cancer].

Kyobu Geka 2021 Feb;74(2):87-91

Department of Thoracic Surgery, Iwate Prefectural Isawa Hospital, Oshu, Japan.

To evaluate the clinical features of patients who developed resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) administered for postoperative recurrence of lung cancer, we assessed eight patients who underwent surgical biopsy or sampling for the detection of T790M mutation under general anesthesia from 2017 to 2019 in our hospital. All 8 patients had undergone lobectomy with nodal dissection for lung cancer of pathological stageⅠB/Ⅲ/Ⅳa (4/3/1 patients). The median disease-free survival was 29 months (range:11~110 months). Read More

View Article and Full-Text PDF
February 2021

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.

Eur J Cancer 2021 May 8;151:115-125. Epub 2021 May 8.

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. Electronic address:

Background: Immuno-oncology (IO)-based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes of trial-ineligible vs. -eligible patients with advanced solid tumours treated with first-line (1L) IO therapy. Read More

View Article and Full-Text PDF

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.

Appl Immunohistochem Mol Morphol 2021 May 12. Epub 2021 May 12.

Agilent Technologies Inc., R&D Agilent Technologies Inc., Histopathology, Carpinteria, CA.

Tumor heterogeneity may impact immunohistochemical (IHC) interpretation, thus potentially affecting decision making by treating oncologists for cancer patient management. Programmed cell death ligand-1 (PD-L1) IHC 22C3 pharmDx is a companion diagnostic used as an aid in identifying patient eligibility for treatment with pembrolizumab (KEYTRUDA). This study aims to investigate tumor heterogeneity impact on IHC staining when evaluating PD-L1 expression using PD-L1 IHC 22C3 pharmDx. Read More

View Article and Full-Text PDF

DDX10 promotes human lung carcinoma proliferation by U3 small nucleolar ribonucleoprotein IMP4.

Thorac Cancer 2021 May 11. Epub 2021 May 11.

Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Background: Lung cancer is a common tumor and a leading cause of death worldwide. DEAD/H box RNA helicases (DDX) include several family members which regulate mRNA translation in cancer cells. In this study, we demonstrated that DEAD/H box RNA helicase 10 (DDX10) was significantly upregulated in lung cancer tissues compared with adjacent nontumor tissues. Read More

View Article and Full-Text PDF